Is it permissible under Medicare regulations to use EzPAP (positive expiratory pressure device), Acapella (oscillating positive expiratory pressure device), Cough Assist (mechanical insufflator‑exsufflator), and Therapy Vest (high‑frequency chest wall oscillation) as a blanket wellness program for skilled nursing facility and long‑term care patients without documented respiratory indications, or does this constitute fraudulent billing?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Blanket Use of Respiratory Devices in SNF/LTC Without Documented Indications is Not Supported by Evidence and Raises Serious Billing Concerns

The routine, facility-wide use of EzPAP, Acapella, Cough Assist, and Therapy Vest devices as a "wellness program" for skilled nursing facility and long-term care patients without documented respiratory indications is not supported by clinical guidelines and constitutes inappropriate billing under Medicare regulations.

Why This Practice is Problematic

Evidence-Based Indications Are Specific, Not Universal

The available clinical practice guidelines are clear about when these devices should be used:

Cough Assist (Mechanical Insufflation-Exsufflation):

  • The American Thoracic Society guidelines specifically recommend cough assist techniques for patients with neuromuscular disease with ineffective cough to maintain airway patency and avoid respiratory complications 1, 2
  • The 2023 American College of Chest Physicians guideline suggests MI-E devices for patients with neuromuscular disease and reduced cough effectiveness that cannot be adequately improved with alternative techniques 3
  • These are targeted interventions for specific pathology, not preventive wellness tools

Acapella (Oscillating Positive Expiratory Pressure):

  • A 2023 randomized controlled trial found benefit in patients with COPD who reported sputum production every day or most days 4
  • The 2013 AARC clinical practice guideline states that airway clearance therapy may be considered in patients with COPD with symptomatic secretion retention, but is not recommended for routine use 5
  • The guideline explicitly states ACT is not recommended if the patient is able to mobilize secretions with cough 5

High-Frequency Chest Wall Oscillation (Therapy Vest):

  • The 2023 ACCP guideline suggests HFCWO only for patients with neuromuscular disease with difficulties with secretion clearance, and recommends it be combined with other airway clearance therapies 3
  • The 2013 AARC guideline found insufficient evidence to recommend high-frequency chest wall compression for patients with neuromuscular disease 5

EzPAP:

  • A 2025 study showed efficacy specifically for hypercapnic COPD exacerbations 6
  • This is an acute intervention for respiratory failure, not a preventive wellness measure

Medicare Coverage Requirements

Medicare regulations require that durable medical equipment and respiratory devices be:

  1. Medically necessary for the individual patient
  2. Prescribed based on documented clinical indications
  3. Used for treatment of a specific diagnosed condition

The 2006 Medicare final rule on respiratory assist devices clarifies payment requirements and emphasizes proper documentation 7. A 2025 review explicitly states these devices have specific indications for conditions like central sleep apnea, hypoventilation, hypercapnic respiratory failure, and restrictive lung disease 8.

What Guidelines Actually Recommend for Prevention

The evidence shows that for patients without documented respiratory pathology:

  • Postoperative patients: Early mobility and ambulation is recommended, but airway clearance therapy is not recommended for routine postoperative care 5
  • Pneumonia: Chest physiotherapy is not recommended for routine treatment of uncomplicated pneumonia 5
  • COPD without symptoms: ACT is not recommended for routine use 5

The Fraud Risk

Billing Medicare for these devices and services across an entire facility population without individualized clinical documentation constitutes:

  1. Lack of medical necessity: The cornerstone of Medicare fraud is billing for services that are not medically necessary
  2. Pattern of abuse: Implementing this across 55 facilities demonstrates systematic rather than isolated inappropriate billing
  3. Financial motivation over clinical indication: The admission that this is done facility-wide regardless of patient diagnosis suggests revenue generation rather than clinical need

What Should Happen Instead

For individual patients, these devices should only be prescribed when:

  • Neuromuscular disease with documented ineffective cough (peak cough flow <270 L/min) 2, 3, 5
  • COPD with daily sputum production and symptomatic secretion retention 5, 4
  • Acute hypercapnic respiratory failure requiring ventilatory support 9
  • Documented respiratory muscle weakness or impaired cough 3, 5

Documentation must include:

  • Specific respiratory diagnosis
  • Objective measurements (spirometry, peak cough flow, etc.)
  • Failed response to simpler interventions
  • Individualized treatment plan with goals

Common Pitfalls to Avoid

  • "Preventive" justification: There is no evidence supporting prophylactic use of these devices in patients without respiratory pathology
  • Blanket protocols: Medicare requires individualized assessment and prescription
  • Assuming all SNF/LTC patients need respiratory therapy: Most do not meet criteria for these specialized devices

Your concerns about fraudulent billing appear well-founded based on the clinical evidence and Medicare regulations. This practice pattern should be reported to appropriate compliance authorities.

Related Questions

Is requiring incentive spirometry, EzPAP (positive airway pressure device), and Acapella (airway clearance device) for all patients breathing room air without a history of respiratory disease medically justified, or could it constitute Medicare fraud?
Should I prescribe the EzPAP (positive expiratory pressure) device for all patients in my chronic tracheostomy and ventilator unit, given that most have hypoxic brain injury or stroke and only a few have neuromuscular respiratory failure or COPD, and can I bill Medicare for its use as a wellness program?
Is the EzPAP (positive airway pressure) system an effective preventive treatment for all residents in skilled‑nursing or long‑term‑care facilities regardless of diagnosis?
When is continuous positive airway pressure (CPAP) indicated versus bilevel positive airway pressure (BiPAP) for treating sleep apnea and related respiratory disorders?
In a hemodynamically stable patient with pneumonia, what physiotherapy interventions (breathing exercises, incentive spirometry, airway‑clearance techniques, early mobilization, and positioning) should be employed?
What are Myambutol (isoniazid/ethambutol) and Biaxin (clarithromycin)?
In a man over 50 with symptomatic benign prostatic hyperplasia who has failed maximal-dose tamsulosin (0.4 mg daily) for 4–6 weeks, what is the next step in management?
What is the mechanism of action, appropriate dosing regimen, and associated risks of using pramipexole to treat anhedonia in a patient with Parkinson disease?
In a patient with suspected type 1 diabetes, especially with atypical features, which autoimmune antibody tests (glutamic acid decarboxylase 65 kDa antibodies [GAD65], insulinoma‑associated antigen‑2 antibodies [IA‑2], zinc transporter‑8 antibodies [ZnT8], and insulin autoantibodies [IAA] if on insulin) should be ordered at diagnosis and how should the results be interpreted?
What is the recommended prednisone taper dosing for pyoderma?
Could a person with facial, lip, and nasal telangiectasias that bleed rarely and a 2.9 cm inferior mesenteric venous varix (not an arteriovenous malformation) have hereditary hemorrhagic telangiectasia?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.